Special Issue

Protein Kinases: Signalling and Disease

Message from the Guest Editor

Protein kinases have become a major drug target for the treatment of a variety of diseases, especially cancer. Kinase inhibitors have been approved for a number of therapeutic indications and will likely continue to expand. One recent example is the small molecule JAK kinase inhibitor. Xelianz (tofacitinib). Originally approved for the treatment of rheumatoid arthritis in 2012, it has received approval this year (2018) the treatment of ulcerative colitis as well. The list of indications for which kinase inhibitors may find use as therapeutic agents continues to grow, including uses for treating viral and parasitic diseases. This Special Issue focuses on the connection between protein kinase signalling and disease, with an emphasis on novel small molecule inhibitors and new therapeutic indications for these agents.

Guest Editor

Prof. Dr. John Siekierka

Sokol Institute for Pharmaceutical Life Sciences and Department of Chemistry and Biochemistry, Montclair State University, Montclair, NJ 07043, USA

Deadline for manuscript submissions

closed (31 May 2020)



Cells

an Open Access Journal by MDPI

Impact Factor 5.2 CiteScore 10.5 Indexed in PubMed



mdpi.com/si/18150

Cells
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cells@mdpi.com

mdpi.com/journal/cells





Cells

an Open Access Journal by MDPI

Impact Factor 5.2 CiteScore 10.5 Indexed in PubMed



About the Journal

Message from the Editorial Board

Cells has become a solid international scientific journal that is now indexed on SCIE and in other databases. We have successfully introduced a special issues format so that these issues serve as mini-forums in specific areas of cell science. Cells encourages researchers to suggest new special issues, serve as special issues editors, and volunteer to be reviewers. Our main focus will remain on cell anatomy and physiology, the structure and function of organelles, cell adhesion and motility, and the regulation of intracellular signaling, growth, differentiation, and aging. We are open to both original research papers and reviews.

Editors-in-Chief

Dr. Alexander E. Kalyuzhny

Dental Basic Sciences, University of Minnesota, 308 Harvard St. SE, Minneapolis, MN 55455, USA

Prof. Dr. Cord Brakebusch

Biotech Research & Innovation Centre, The University of Copenhagen, Copenhagen, Denmark

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Cell Biology) / CiteScore - Q1 (General Biochemistry, Genetics and Molecular Biology)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16 days after submission; acceptance to publication is undertaken in 2.7 days (median values for papers published in this journal in the first half of 2025).

